Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma

Clinical Cancer Research

Volumn 3, Issue 1, 1997, Pages 17-24

  Soiffer, Robert J ^a   Chapman, Paul B ^b   Murray, Christine ^b   Williams, Linda ^b   Unger, Paul ^b   Collins, Heather ^b   Houghton, Alan N ^b   Ritz, Jerome ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; DIPHENHYDRAMINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R24; PARACETAMOL; RECOMBINANT INTERLEUKIN 2;

ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOLYSIS; FEVER; HUMAN; HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LUNG TOXICITY; MELANOMA; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THYROID DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031042925     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kohler, G., and Milstein, C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature (Lond.), 256: 495- 501, 1975.
2. Grossbard, M. L., Press, O. W., Appelbaum, F. R., Bernstein, I. D., and Nadler, L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood, 80: 863-878, 1992.
3. Maloney, D. G., Liles, T. M., Czerwinski, D. K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., and Levy, R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84: 2457-2466, 1994.
4. Houghton, A. N., and Scheinberg, D. A. Monoclonal antibodies: potential applications to the treatment of cancer. Semin. Oncol., 13: 165-179, 1986.
5. Sears, H. F., Herlyn, D., Steplewski, Z., and Koprowski, H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J. Biol. Response Modif., 3: 138-150, 1984.
6. Dippold, W. G., Dienes, H. P., Knuth, A., and Meyer zum Buschenfelde, K. H. Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors and normal tissues. Cancer Res., 45: 3699-3705, 1985.
7. Urmacher, C., Cordon-Cardo, C., and Houghton, A. Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. Am. J. Dermatol., 11: 577-581, 1989.
8. Cheresh, D. A., Reisfeld, R. A., and Varki, A. J. O-Acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic epitope. Science (Washington DC), 225: 844-850, 1984.
9. Hamilton, W. B., Helling, F., Lloyd, K. O., and Livingston, P. O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer, 53: 566-573, 1993.
10. Hersey, P., Schibeci, S. D., Townsend, P., Burns, C., and Cheresh, D. A. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3. Cancer Res., 46: 6083-6090, 1986.
11. Vadhan-Rai, S., Cordon-Cardo, C., Carswell, E., Mintzer, D., Dantis, L., Duteau, C., Templeton, M. A., Oettgen, H. F., Old, L. J., and Houghton, A. N. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J. Clin. Oncol., 6: 1636-1648, 1988.
12. Houghton, A. N., Mintzer, D., and Gordon-Cardo, C. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA, 1985: 1242-1246, 1985.
13. Bukowski, R. M., Murthy, S. A., Finke, J., Caulfield, M. J., Tubbs, R., Herzog, P., Stanley, J., Edinger, M., Tuason, L., and McLain, D. Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects. J. Immunother. Emphasis Tumor Immunol., 15: 273-282, 1994.
14. Bajorin, D. F., Chapman, P. B., Wong, G. Y., Cody, B. V., Cordon- Cardo, C., Dantes, L., Templeton, M. A., Scheinberg, D., Oettgen, H. F., and Houghton, A. N. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res., 2: 355-362, 1992.
15. Dippold, W. G., Knuth, A., and Mewyer zum Buschenfelde, K. H. Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res., 44: 806-810, 1984.
16. Cheresh, D. A., Honsik, C. J., Staffileno, L. K., Jung, G., and Reisfeld, R. A. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc. Natl. Acad. Sci. USA, 82: 5155-5159, 1985.
17. Welte, S., Carswell, E. A., Vogel, C. W., Oettgen, H. F., and Old, L. J. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin. Immunol. Immunopathol., 45: 214-229, 1987.
18. Harel, W., Shau, H., Hadley, C. G., Morgan, A. C. J., Reisfeld, R. A., Cheresh, D. A., and Mitchell, M. S. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Cancer Res., 50: 6311-6315, 1990.
19. Caligiuri, M., Murray, C., Robertson, M., Wang, E., Cochran, K., Cameron, C., Schow, P., Ross, M., Klumpp, T., Soiffer, R., Smith, K., and Ritz, J. Selective modulation of human natural killer cells in vivo following prolonged infusion of low-dose recombinant interleukin-2. J. Clin. Invest., 91: 123-132, 1993.
20. Caligiuri, M., Murray, C., Soiffer, R., Klumpp, T., Seiden, M., Cochran, K., Cameron, C., Ish, C., Buchanan, L., Perillo, D., Smith, K., and Ritz, J. Extended continuous infusion of low dose recombinant IL-2 in advanced cancer: prolonged immune modulation without significant toxicity. J. Clin. Oncol., 9: 2110-2119, 1991.
21. Soiffer, R. J., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P. W., Daley, J. F., and Ritz, J. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 79: 517-526, 1992.
22. Soiffer, R. J., Murray, C., Shapiro, C., Collins, H., Chartier, S., Lazo, S., and Ritz, J. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion of intermittent bolus administration of interleukin 2. Clin. Cancer Res., 2: 493-499, 1996.
23. Nagler, A., Lanier, L., and Phillips, L. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J. Exp. Med., 171: 1527-1533, 1990.
24. Smith, K. A. Lowest dose interleukin-2 immunotherapy. Blood, 81: 1414-1423, 1993.
25. Herlyn, D. M., and Koprowski, H. Monoclonal anticolon carcinoma antibodies in complement-mediated cytotoxicity. Int. J. Cancer, 27: 769-775, 1981.
26. Ortaldo, J. R., Woodhouse, C., Morgan, A. C., Herberman, R. B., Cheresh, D. A., and Reisfeld, R. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J. Immunol., 138: 3566-3572, 1987.
27. Hellstrom, I., Garrigues, U., Lavie, E., and Hellstrom, K. E. Antibody-mediated killing of human tumor cells by attached effector cells. Cancer Res., 48: 624-627, 1988.
28. Robertson, M. J., Caligiuri, M. A., Manley, T. J., Levine, H., and Ritz, J. Human natural killer cell adhesion molecules: differential expression after activation and participation in cytolysis. J. Immunol., 145: 3194-3201, 1990.
29. Margolin, K., Rayner, A., Hawkins, M., Atkins, M., Dutcher, J., Fisher, R., Weiss, G., Doroshow, J., Jaffe, H., Roper, M., Parkinson, D., Weirnik, P., Creekmore, S., and Boldt, D. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol., 7: 486-498, 1989.
30. Siegel, J. P., and Puri, R. K. Interleukin-2 toxicity. J. Clin. Oncol., 9: 694-704, 1991.
31. Natali, P. G., Bigotti, A., Nicotra, M. R., Nardi, R. M., Delovu, A., Segatto, O., and Ferrone, S. Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Cancer Res., 49: 1269-1274, 1989.
32. Bajorin, D. F., Chapman, P. B., Wong, G., Coit, D. G., Kunicka, J., Dimaggio, J., Cordon-Cardo, C., Urmacher, C., Dantes, L., Templeton, M. A., et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res., 50: 7490-7495, 1990.
33. Creekmore, S., Urba, W., Kopp, W., Ewel, C., Hecht, T., Smith, J., Janik, J., Steis, R., Fenton, R., Sharfman, W., Conlon, K., Sznol, M., Holmlund, J., Curti, B., Gause, B., Houck, M., Beveridge, J., Jones, M., and Longo, D. Phase IB/II trial of R24 antibody and interleukin-2 (IL2) in melanoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 11: A1186, 1992.
34. Chapman, P. B., Gillies, S. D., Houghton, A. N., and Reilly, R. M. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody. Cancer Immunol. Immunother., 39: 198-204, 1994.
35. Hale, G., Dyer, M. J. S., Clark, M. R., Phillips, J. M., Marcus, R., Riechmann, L., Winter, G., and Waldmann, H. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet, 2: 1394-1399, 1988.
36. Chachoua, A., Oratz, R., Liebes, L., Alter, R. S., Felice, A., Peace, D., Vilcek. J., and Blum, R. H. Phase Ib trial of granulocyte-macrophage colony stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J. Immunother., 16: 132- 141, 1994.
37. Minasian, L. M., Szatrowski, T. P., Rosenblum, M., Steffens, T., Morrison, M. E., Chapman, P. B., Williams, L., Nathan, C. F., and Houghton, A. N. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood, 83: 56-64, 1994.
38. Caulfield, M. J., Barna, B., Murthy, S., Tubbs, R., Sergi, J., Medendorp, S., and Bukowski, R. M. Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-α in patients with malignant melanoma. J. Biol. Response Modif., 9: 319-328, 1990.
39. Steffens, T. A., Bajorin, D. F., Williams, L. J., Chapman, P. B., Dantes, L. A., Toomey, M. M., Oettgen, H. F., and Houghton, A. N. A phase I trial of R24 monoclonal antibody (MAB) and recombinant human macrophage colony stimulating factor (RHM-CSF) in patients (pts) with advanced melanoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 11: A1182, 1992.
40. Welte, K., Miller, G., Chapman, P. B., Yuasa, H., Natoli, E., Kunicka, J. E., Cordon-Cardo, C., Buhrer, C., Old, L. J., and Houghton, A. N. Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J. Immunol., 139: 1763-1771, 1987.
41. Norihisa, Y., McVicar, D., Ghosh, P., Houghton, A. N., Longo, D. L., Creekmore, S. P., Ortaldo, J. R., and Young, H. A. Increased proliferation, cytotoxicity and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3). J. Immunol., 152: 485-495, 1994.
42. Boussiotis, V. A., Pardo, N. A., Collins, H., Houghton, A., Ritz, J., Nadler, L. M., and Soiffer, R. J. Prevention of alloantigen specific T cell anergy by ligation of GD3 ganglioside. Eur. J. Immunol., 26: 2149- 2154, 1996.
43. Boussiotis, V. A., Barber, D. L., Nakarai, T., Freeman, G. J., Gribben, J. G., Bernstein, G. M., D'Andrea, A. L., Ritz, J., and Nadler, L. M. Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor. Science (Washington DC), 266: 1039-1042, 1994.